StockGlow

TG Therapeutics, Inc. (NKB2.F)

TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally.

46.00-0.00%Healthcare
Compare NKB2.F with
StockGlow Score
90
Bullish
BearishBullish
1 year ago+50.5%

The outlook

TG Therapeutics, Inc. currently reads as bullish based on above its 50- & 200-day averages, 82% of the way from its 52-week low to high. This is a snapshot of current market data, not a forecast.

What’s behind the score

Price trendAbove its 50- & 200-day averages
52-week range82% of the way from its 52-week low to high
Market cap
$7.04B
52-wk high
51.20
52-wk low
22.47
50-day avg
43.06
200-day avg
31.24
Trailing P/E
18.3

Similar stocks

DR6.FACADIA Pharmaceuticals Inc.$23.02+0.61%38I.FIntellia Therapeutics, Inc.$9.30+1.53%2L9.FVisionWave Holdings, Inc.$1.63-3.66%KK3A.FCytokinetics, Incorporated$69.26-1.34%UP0.FUltragenyx Pharmaceutical Inc.$22.52+4.89%

The StockGlow Score is a snapshot of current, observable market data (analyst ratings, price trend, 52-week range) — not a prediction, forecast, or recommendation. Informational only, not investment advice. Data from public sources and may be delayed. How this works·Privacy